Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011 Oct 06; 118(14):3922-31.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.